Medicenna Therapeutics is an immunotherapy company that develops and commercializes Superkines and empowered Superkines for cancer and other diseases. Their primary product is MDNA55, used to treat recurrent glioblastoma, as well as other brain and non-brain tumors. They also provide designer Superkines through their BiSKITs platform by fusing them to other proteins, antibodies, cytokines, or other Superkines.